Results 361 to 370 of about 168,682 (384)

CD20 Inhibitors: Rituximab

2015
The CD20 inhibitors are protein constructs which bind and inactivate CD20. They are members of a group of drugs active in rheumatoid arthritis known as biological disease-modifying antirheumatic drugs (bDMARDs). They are not included in the group slow-acting antirheumatic drugs (SAARDs) because they are considered to have more specific actions and ...
Garry G. Graham, Garry G. Graham, Kevin D. Pile, Stephen M. Mahler   +3 more
openaire   +4 more sources

P138 Modulation of CD20 expression on B cells by anti-CD20 antibodies

Human Immunology, 2016
Abstract The purpose of this communication is to describe a case that illustrates the interference of in vivo anti-CD20 treatment on B cell crossmatch (B-XM) results. A first kidney transplant candidate, female, white, 31 years-old, with systemic lupus erythematosus, without previous pregnancies, with one blood transfusion more than 15 years ago ...
Tiago Valim, Elaine C. Bellintani, Julia Temin, Yuriko Miyamoto, Denise Macedo, Renato de Marco, Renata Fantini   +6 more
openaire   +2 more sources

Glofitamab CD20-TCB bispecific antibody

Leukemia & Lymphoma, 2021
Bispecific T-cell recruiting antibodies are emerging as a potent immunotherapeutic class in the treatment of B-cell malignancies and act by simultaneously targeting antigens on T-cells and malignant cells to effect tumor cell death. Glofitamab is a novel full-length IgG-like CD20-CD3 bispecific with a unique 2:1 configuration that provides an extended ...
Adrian Minson, Adrian Minson, Michael Dickinson, Michael Dickinson   +3 more
openaire   +2 more sources

Statins Impair Antitumor Effects of CD20 mAb by Inducing Conformational Changes of CD20.

Blood, 2007
Abstract A number of monoclonal antibodies (mAb) are presently in development or approved for CD20-directed immunotherapy. Ofatumumab, a human IgG1 anti-CD20 mAb, is currently being evaluated in phase III clinical trials for B-CLL and FL, and in phase II clinical trials for rheumatoid arthritis (RA).
Paul W. H. I. Parren, Tomasz Stoklosa, M Wasik, Wendy J.M. Mackus, Eliza Glodkowska, Małgorzata Lekka, Zbigniew Gaciong, Grzegorz M. Wilczynski, Maciej Siński, Krzysztof Warzocha, Elżbieta Górska, Piotr Mrowka, Anna Dabrowska-Iwanicka, Marcin Makowski, Dominika Nowis, Patrick J. Engelberts, Magdalena Winiarska, Jacek Bil, Tadeusz Issat, Marek Jakóbisiak, Jakub Golab, Witold Lasek, Ewa Wilczek   +22 more
openaire   +2 more sources

Inhibitory FcγRIIb and CD20 internalization

Blood, 2014
In this issue of Blood, Vaughan et al demonstrate that certain antibodies that are used therapeutically in lymphoma treatment (e.g., rituximab) undergo Fcg receptor IIb (FcgRIIb)–mediated internalization from the B-cell surface in a manner that is independent of activation of FcgRIIb with important implications for the design of antibody-based ...
openaire   +2 more sources

Immunotherapy with anti-CD20 compounds

Seminars in Cancer Biology, 2003
The B-cell surface antigen CD20 is currently the prime target for near-selective treatment of mature B-cell malignancies and a range of reactive B-cell associated disorders (including virus-associated lymphoproliferation or autoimmune conditions). CD20 is strongly and homogeneously expressed on the majority of mature B-cell neoplasms except chronic ...
openaire   +3 more sources

CD20 Trek: the next generation [PDF]

Blood, 2004
Comment on Teeling et al, page [1793][1] A collaboration between investigators in basic science and biotechnology has produced a new set of human mAbs which may have superior efficacy in the immunotherapy of B-cell lymphoma.
openaire   +1 more source

Neuer CD20-Antikörper

Info Onkologie, 2016
Follikulare Lymphome (FL) werden meist im fortgeschrittenen Stadium entdeckt, sodass eine palliative Therapie gefragt ist. Bei vorbehandelten Patienten mit Progress steht nun mit Obinutuzumab plus Bendamustin eine wirksame Alternative zur Verfugung.
openaire   +2 more sources

CD20-negative follicular lymphoma

Diagnostic Histopathology, 2012
Abstract Follicular lymphoma is one of the commoner diagnosed Non-Hodgkin Lymphomas (NHL) of adults in the North America and Europe. It is a B-cell lymphoma, composed of neoplastic centrocytes and centroblasts that express the pan-B cell antigens CD20 and CD79a and the follicle centre markers CD10 and bcl-6.
Annette Riley, Orla H. O'Mahony
openaire   +2 more sources

Establishment of an Anti-CD20 Monoclonal Antibody (C20Mab-60) for Immunohistochemical Analyses.

Monoclonal antibodies in immunodiagnosis and immunotherapy, 2020
Sensitive and specific monoclonal antibodies (mAbs) are needed for detecting CD20. This antigen, one of several B lymphocyte antigens, is a target for every application used in the diagnosis of B cell lymphoma.
Yoshikazu Furusawa, M. Kaneko, Y. Kato
semanticscholar   +1 more source